Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real-world data and direct comparisons are scarce. This real-life study explored the safety profile of pirfenidone an...

Descripción completa

Detalles Bibliográficos
Autores principales: Levra, Stefano, Guida, Giuseppe, Sprio, Andrea Elio, Crosa, Flavio, Ghio, Paolo Carlo, Bertolini, Francesca, Carriero, Vitina, Albera, Carlo, Ricciardolo, Fabio Luigi Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775369/
https://www.ncbi.nlm.nih.gov/pubmed/36551989
http://dx.doi.org/10.3390/biomedicines10123229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775369/
https://www.ncbi.nlm.nih.gov/pubmed/36551989
http://dx.doi.org/10.3390/biomedicines10123229

Ejemplares similares